![]() | Current customer? Log In |
| |
| Search Departments
More Ways to Shop
Free Catalog
Newsletter Sign Up
Weekly health news, sale announcements and coupons!
|
Library Home
> Safetychecker by Drug Name > Valproic Acid
VALPROIC ACIDVisit The Healthy Living Bookshelf:
Valproic acid, divalproex sodium, and sodium valproate are closely related drugs used to control (prevent) seizures in people with epilepsy. Safetychecker Summary
for Valproic Acid
Interactions with Dietary Supplements
Antioxidants Biotin
Calcium
Carnitine Complete disappearance of severe valproic acid-induced abdominal pain was achieved in one child with intractable epilepsy immediately following the introduction of 300 mg per day of L-carnitine.12 Carnitine supplementation (50 mg per 2.2 pounds of body weight) has protected children from valproic acid-induced increases in blood ammonia levels in some research,13 though other published work has questioned whether the depletion of carnitine and the increase in blood ammonia levels (both caused by valproic acid) are actually related to each other.14 This last report found that the depletion of carnitine was significantly more severe when epileptics were taking valproic acid together with other anti-seizure medications. A double-blind, crossover study found that carnitine supplementation (100 mg per 2.2 pounds of body weight) was no more effective than placebo in improving the sense of well-being in children treated with valproic acid.15 To date, the question of whether carnitine supplementation is beneficial for people taking valproic acid remains unresolved.16 However, a panel of pediatric neurologists and experts on L-carnitine supplementation strongly recommended oral L-carnitine supplementation for all infants and children taking valproic acid, as well as for adults with carnitine deficiency syndromes, people with valproic acid-induced liver and kidney toxicity, people on kidney dialysis, and premature infants on total parenteral nutrition (intravenous feeding). The panel recommended an amount of 100 mg per 2.2 pounds of body weight per day, up to a maximum of 2 grams per day.17 Copper and Zinc Folic
acid One preliminary study showed that pregnant women who use anticonvulsant drugs without folic acid supplementation have an increased risk of having a child with birth defects, such as heart defects, cleft lip and palate, neural tube defects, and skeletal abnormalities. However, supplementation with folic acid greatly reduces the risk.28 Consequently, some healthcare practitioners recommend that women taking multiple anticonvulsant drugs supplement with 5 mg of folic acid daily, for three months prior to conception and during the first trimester, to prevent folic acid deficiency-induced birth defects.29 Other practitioners suggest that 1 mg or less of folic acid each day is sufficient to prevent deficiency during pregnancy.30 One well-controlled study showed that adding folic acid to multiple anticonvulsant therapy resulted in reduced seizure frequency.31 In addition, three infants with seizures who were unresponsive to medication experienced immediate relief following supplementation with the active form of folic acid.32 Despite the apparent beneficial effects, some studies have indicated that as little as 0.8 mg of folic acid taken daily can increase the frequency and/or severity of seizures.33 34 35 36 However, a recent controlled study showed that both healthy and epileptic women taking less than 1 mg of folic acid per day had no increased risk for seizures.37 Until more is known about the risks and benefits of folic acid, individuals taking multiple anticonvulsant drugs should consult with their healthcare practitioner before supplementing with folic acid. In addition, pregnant women or women who might become pregnant while taking anticonvulsant drugs should discuss folic acid supplementation with their practitioner. Vitamin
A Vitamin
B6 Vitamin
B12 Vitamin
D Vitamin
E Vitamin
K Interactions with Foods and Other Compounds Food Alcohol References: 1. Nurge ME, Anderson CR, Bates E. Metabolic and nutritional implications of valproic acid. Nutr Res 1991;11:949–60. 2. Mock DM, Dyken ME. Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants. Neurology 1997;49:1444–7. 3. Mock DM, Mock NI, Nelson RP, Lombard KA. Disturbances in biotin metabolism in children undergoing long-term anticonvulsant therapy. J Pediatr Gastroenterol Nutr 1998;26:245–50. 4. Krause KH, Bonjour JP, Berlit P, Kochen W. Biotin status of epileptics. Ann NY Acad Sci 1985;447:297–313. 5. Krause KH, Bonjour JP, Berlit P, et al. Effect of long-term treatment with antiepileptic drugs on the vitamin status. Drug Nutr Interact 1988;5:317–43. 6. Bouillon R, Reynaert J, Claes JH, et al. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975;41:1130–5. 7. Friis B, Sardemann H. Neonatal hypocalcaemia after intrauterine exposure to anticonvulsant drugs. Arch Dis Child 1977;52:239–41. 8. Van Wouwe JP. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 1995;65:211–4. 9. Castro-Gago M, Camina F, Rodriguezx-Segade S. Carnitine deficiency caused by valproic acid. J Pediatr 1992;120:496 [letter]. 10. Hirose S, Mitsudome A, Yasumoto S, et al. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998;101:E9. 11. Stanley CA. Carnitine disorders. Adv Pediatr 1995;42:209–42. 12. Shuper A, Gutman A, Mimouni M. Intractable epilepsy. Lancet 1999;353:1238. 13. Gidal BE, Inglese CM, Meyer JF, et al. Diet-and valproate-induced transient hyperammonemia: Effect of L-carnitine. Pediatr Neurol 1997;16:301–5. 14. Verotti A, Greco R, Morgese G, Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 1999;29:36–40. 15. Freeman JM, Vining EPG, Cost S, Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, crossover study. Pediatrics 1994;93:893–5. 16. Kelley RI. The role of carnitine supplementation in valproic acid therapy. Pediatrics 1994;93:891–2 [editorial]. 17. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998;39:1216–25. 18. Kaji M, Ito M, Okuno T, et al. Serum copper and zinc levels in epileptic children with valproate treatment. Epilepsia 1992;33:555–7. 19. Lerman-Sagie T, Statter M, Szabo G, Lerman P. Effect of valproic acid therapy on zinc metabolism in children with primary epilepsy. Clin Neuropharmacol 1987;10:80–6. 20. Sozuer DT, Barutcu UB, Karakoc Y, et al. The effects of antiepileptic drugs on serum zinc and copper levels in children. J Basic Clin Physiol Pharmacol 1995;6:265–9. 21. Sozuer DT, Barutcu UB, Karakoc Y, et al. The effects of antiepileptic drugs on serum zinc and copper levels in children. J Basic Clin Physiol Pharmacol 1995;6:265–9. 22. Lerman-Sagie T, Statter M, Szabo G, Lerman P. Effect of valproic acid therapy on zinc metabolism in children with primary epilepsy. Clin Neuropharmacol 1987;10:80–6. 23. Kaji M, Ito M, Okuno T, et al. Serum copper and zinc levels in epileptic children with valproate treatment. Epilepsia 1992;33:555–7. 24. Lerman-Sagie T, Statter M, Szabo G, Lerman P. Effect of valproic acid therapy on zinc metabolism in children with primary epilepsy. Clin Neuropharmacol 1987;10:80–6. 25. Hendel J, Dam M, Gram L, et al. The effects of carbamazepine and valproate on folate metabolism in man. Acta Neurol Scand 1984;69:226–31. 26. Apeland T, Mansoor MA, Strandjord RE, Kristensen O. Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol Scand 2000;101:217–23. 27. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999;40:345–50. 28. Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 1984;18:211–6. 29. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs 1999;57:535–44 [review]. 30. Hiilesmaa VK, Teramo K, Granstrom JL, et al. Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. Br Med J (Clin Res Ed) 1983;287:577–9. 31. Gibberd FB, Nicholls A, Wright MG. The influence of folic acid on the frequency of epileptic attacks. Eur J Clin Pharmacol 1981;19:57–60. 32. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. J Child Neurol 1999;14:529–32. 33. Guidolin L, Vignoli A, Canger R. Worsening in seizure frequency and severity in relation to folic acid administration. Eur J Neurol 1998;5:301–3. 34. Lewis DP, Van Dyke DC, Willhite LA. Phenytoin-folic acid interaction. Ann Pharmacother 1995;29:726–35 [review]. 35. Berg MJ, Rivey MP, Vern BA, et al. Phenytoin and folic acid: individualized drug-drug interaction. Ther Drug Monit 1983;5:395–9. 36. Reynolds EH. Effects of folic acid on the mental state and fit frequency of drug treated epileptic patients. Lancet 1967;1:1086. 37. Eros E, Geher P, Gomor B, Czeizel AE. Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy). Eur J Obstet Gynecol Reprod Biol 1998;80:75–8. 38. Nau H, Tzimas G, Mondry M, et al. Antiepileptic drugs alter endogenous retinoid concentrations: a possible mechanism of teratogensis of anticonvulsant therapy. Life Sci 1995;57:53–60. 39. Reinken L. The influence of antiepileptic drugs on vitamin B6 metabolism. Acta Vitaminol Enzymol 1975;291:252–4. 40. Ito M, Okuno T, Hattori H, et al. Vitamin B6 and valproic acid in treatment of infantile spasms. Pediatr Neurol 1991;7:91–6. 41. Frenkel EP, McCall MS, Sheehan RG. Cerebrospinal fluid folate, and vitamin B12 in anticonvulsant-induced megaloblastosis. J Lab Clin Med 1973;81:105–15. 42. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999;40:345–50. 43. Telci A, Cakatay U, Kurt BB, et al. Changes in bone turnover and deoxypyridinoline levels in epileptic patients Clin Chem Lab Med 2000 38:47–50. 44. Jekovec-Vrhovsek M, Kocijancic A, Prezelj J. Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full-time care. Dev Med Child Neurol 2000;42:403–5. 45. Riancho JA, Del Arco C, Arteaga R, et al. Influence of solar irradiation on vitamin D levels in children on anticonvulsant drugs. Acta Neurol Scand 1989;79:296–9. 46. Williams C, Netzloff M, Folkerts L, et al. Vitamin D metabolism and anticonvulsant therapy: effect of sunshine on incidence of osteomalacia. South Med J 1984;77:834. 47. Higashi A, Tamari H, Ikeda T, et al. Serum vitamin E concentration in patients with severe multiple handicaps treated with anticonvulsants. Pediatr Pharmacol (New York) 1980;1:129–34. 48. Higashi A, Ikeda T, Matsukura M, Matsuda I. Serum zinc and vitamin E concentrations in handicapped children treated with anticonvulsants. Dev Pharmacol Ther 1982;5:109–13. 49. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol 1993;168:923–8. 50. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs 1999;57:535–44 [review]. 51. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol 1993;168:884–8. 52. Hey E. Effect of maternal anticonvulsant treatment on neonatal blood coagulation. Arch Dis Child Fetal Neonatal Ed 1999;81:F208–10. 53. Threlkeld DS, ed. Central Nervous System Drugs, Anticonvulsants, Valproic Acid and Derivatives. In Facts and Comparisons Drug Information. St. Louis, MO: Facts and Comparisons, May 1997, 284b–4g. 54. Threlkeld DS, ed. Central Nervous System Drugs, Anticonvulsants, Valproic Acid and Derivatives. In Facts and Comparisons Drug Information. St. Louis, MO: Facts and Comparisons, May 1997, 284b–4g. 55. Threlkeld DS, ed. Central Nervous System Drugs, Anticonvulsants, Valproic Acid and Derivatives. In Facts and Comparisons Drug Information. St. Louis, MO: Facts and Comparisons, May 1997, 284b–4g. Copyright © 2002 Healthnotes, Inc. All rights reserved. www.healthnotes.com Please read the disclaimer about the limitations of the information provided here. Do NOT rely solely on the information in this article. Learn more about Healthnotes, the company. Learn more about the authors of Safetychecker. The information presented in Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2003. |
||||||||||||||
| Ordering Help | Shipping & Returns | Have Questions? | Other Services |
![]() |
Order By Phone 1-800-439-5506
Information on this site is provided for informational purposes and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication. Information about each product is taken from the labels of the products or from the manufacturer's advertising material. MotherNature.com is not responsible for any statements or claims that various manufacturers make about their products. We cannot be held responsible for typographical errors or product formulation changes. You should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.All discounts are taken from suggested retail prices.
Please see our Terms of Use
Copyright © 1995-2008 Mother Nature, Inc. All rights reserved.